Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10940141 | 0.77 | TSHR (0.41) | TSHRCYP1A2KIF11MAPK1 | |
| SCHEMBL19064319 | 0.77 | KIF11 (0.38) | TSHRKCNN4ALDH1A1CYP1A2TAAR1 | |
| SCHEMBL9358740 | 0.75 | KCNN4 (0.35) | KCNN4ALDH1A1TAAR1CYP2C9CYP2C19 | |
| SCHEMBL9320828 | 0.74 | CYP1A2 (0.56) | TSHRKCNN4CYP1A2TAAR1CYP2C9 | |
| SCHEMBL863752 | 0.74 | KCNN4 (0.44) | TSHRKCNN4ALDH1A1CYP1A2TAAR1 | |
| SCHEMBL7517713 | 0.74 | KCNN4 (0.38) | TSHRKCNN4ALDH1A1CYP1A2TAAR1 | |
| SCHEMBL11306527 | 0.72 | TSHR (0.48) | TSHRKCNN4ALDH1A1CYP1A2TAAR1 | |
| SCHEMBL8208883 | 0.72 | TSHR (0.48) | TSHRKCNN4ALDH1A1CYP1A2TAAR1 | |
| SCHEMBL4660210 | 0.72 | KIF11 (0.38) | KCNN4CYP1A2CYP2C9CYP2C19KIF11 | |
| SCHEMBL7157506 | 0.70 | TSHR (0.52) | TSHRKCNN4ALDH1A1CYP1A2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031506-A | Chiral control | 波涛生命科学有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12583883-B2 | Asymmetric auxiliary group | WAVE LIFE SCIENCES LTD. (SG) | 2026-03-24 | — | — | US | disclosed |
| US-20260055133-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS | WAVE LIFE SCIENCES LTD (SG) | 2026-02-26 | — | — | US | disclosed |
| US-12428442-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2025-09-30 | — | — | US | disclosed |
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| US-20240174710-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS | WAVE LIFE SCIENCES LTD. (SG) | 2024-05-30 | — | — | US | disclosed |
| US-11718638-B2 | Compounds, compositions and methods for synthesis | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-08 | — | — | US | disclosed |
| EP-4219516-A2 | CHIRAL CONTROL | Wave Life Sciences Ltd. (SG) | 2023-08-02 | — | — | EP | disclosed |
| US-11643657-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-09 | — | — | US | disclosed |
| EP-2872147-B1 | METHOD FOR MAKING CHIRAL OLIGONUCLEOTIDES | WAVE LIFE SCIENCES LTD (SG) | 2022-12-21 | — | — | EP | disclosed |
| US-7229609-B2 | Diarylbutadiene-substituted methyltrialkylsilanes and photoprotective compositions comprised thereof | L'OREAL (FR) | 2007-06-12 | — | — | US | disclosed |
| US-20060018848-A1 | Photoprotective compositions comprising methyltrialkylsilanes containing a cinnamate, cinnamamide, benzalmalonamide or benzalmalonate function | L'OREAL (FR) | 2006-01-26 | — | — | US | disclosed |
| US-20050201957-A1 | Diarylbutadiene-substituted methyltrialkylsilanes and photoprotective compositions comprised thereof | L'OREAL (FR) | 2005-09-15 | — | — | US | disclosed |
| EP-1535925-A1 | 4,4-Diarylbutadiene functionalized methyltrialkylsilanes and cosmetic or photoprotective dermatological compositions containing them | L'OREAL (FR) | 2005-06-01 | — | — | EP | disclosed |
| EP-0900225-B1 | ALKYL-4-SILYL-PHENOLS AND ESTERS THEREOF AS ANTIATHEROSCLEROTIC AGENTS | AVENTIS PHARMA INC (US) | 2002-01-30 | — | — | EP | disclosed |
| US-5608095-A | Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents | HOECHST MARION ROUSSEL, INC. (US) | 1997-03-04 | — | — | US | disclosed |
| EP-0710241-A1 | NOVEL SILYLATED BENZYLAMINE DERIVATIVES, SALTS THEREOF, METHODS OF MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PIERRE FABRE MEDICAMENT (FR) | 1996-05-08 | — | — | EP | disclosed |
| WO-1995003313-A1 | NOVEL SILYLATED BENZYLAMINE DERIVATIVES, SALTS THEREOF, METHODS OF MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PIERRE FABRE MEDICAMENT (FR) | 1995-02-02 | — | — | WO | disclosed |
| EP-0068813-B1 | FUNGICIDAL 1,2,4-TRIAZOLE AND IMIDAZOLE DERIVATIVES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-09-25 | — | — | EP | disclosed |
| EP-0068813-A2 | Fungicidal 1,2,4-triazole and imidazole derivatives | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718638-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | TSHR 3918/4885KCNN4 4130/4885ALDH1A1 2134/4885 |
| US-20060018848-A1 | Photoprotective compositions comprising methyltrialkylsilanes containing a cinnamate, cinnamamide, benzalmalonamide or benzalmalonate function | TRPM7, TRPM6, KCNN1 | TSHR 4842/4885KCNN4 289/4885ALDH1A1 636/4885 |
| US-20050201957-A1 | Diarylbutadiene-substituted methyltrialkylsilanes and photoprotective compositions comprised thereof | MGMT, DDB1, ERCC1 | TSHR 4745/4885KCNN4 2123/4885ALDH1A1 333/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | TSHR 3259/4885KCNN4 2759/4885ALDH1A1 2867/4885 |
| US-12583883-B2 | Asymmetric auxiliary group | AGL, RNMT, NSUN2 | TSHR 3988/4885KCNN4 1322/4885ALDH1A1 1865/4885 |
| US-12428442-B2 | Compounds, compositions and methods for synthesis | ALKBH1, DUT, RNGTT | TSHR 3918/4885KCNN4 4130/4885ALDH1A1 2134/4885 |
| US-20260055133-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS | NSUN2, NSUN3, NOP2 | TSHR 2106/4885KCNN4 2465/4885ALDH1A1 3107/4885 |
| US-11643657-B2 | Chiral control | RNGTT, POLI, NSUN3 | TSHR 3259/4885KCNN4 2759/4885ALDH1A1 2867/4885 |
| US-20240174710-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS | ALKBH1, DUT, RNGTT | TSHR 3918/4885KCNN4 4130/4885ALDH1A1 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.